A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

van den Bent, Martin; Azaro, Analia; De Vos, Filip; Sepulveda, Juan; Yung, W. K. Alfred; Wen, Patrick Y.; Lassman, Andrew B.; Joerger, Markus; Tabatabai, Ghazaleh; Rodon, Jordi; Tiedt, Ralph; Zhao, Sylvia; Kirsilae, Tiina; Cheng, Yi; Vicente, Sergio; Balbin, O. Alejandro; Zhang, Hefei; Wick, Wolfgang

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Autor(en):

van den Bent, Martin; Azaro, Analia; De Vos, Filip; Sepulveda, Juan; Yung, W. K. Alfred; Wen, Patrick Y.; Lassman, Andrew B.; Joerger, Markus; Tabatabai, Ghazaleh; Rodon, Jordi; Tiedt, Ralph; Zhao, Sylvia; Kirsilae, Tiina; Cheng, Yi; Vicente, Sergio; Balbin, O. Alejandro; Zhang, Hefei; Wick, Wolfgang

Tübinger Autor(en):

Tabatabai, Ghazaleh

Erschienen in:

Journal of Neuro - Oncology (2019), Bd. 146, H. 1, S. 79-89

Verlagsangabe:

Springer

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1007/s11060-019-03337-2

ISSN:

1573-7373